# An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

> **NCT06008938** · — · RECRUITING · sponsor: **CSL Behring** · enrollment: 500 (estimated)

## Conditions studied

- Hemophilia B

## Interventions

- **GENETIC:** HEMGENIX
- **BIOLOGICAL:** Factor IX (FIX)

## Key facts

- **NCT ID:** NCT06008938
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-15
- **Primary completion:** 2043-08-01
- **Final completion:** 2043-08-01
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06008938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06008938, "An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06008938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*